Jasper Therapeutics Inc (JSPR) saw its stock price surge on Monday after releasing positive preliminary data from its SPOTLIGHT Phase 1b/2a study. Briquilimab, the company’s investigational treatment, demonstrated significant clinical response in patients with cold urticaria and symptomatic dermographism, leading to a 5.93% jump in JSPR stock during premarket trading.